Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

SML2308

Sigma-Aldrich

Atazanavir sulfate

≥95% (HPLC)

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
(3S,8S,9S,12S)-1,14-Dimethyl-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate sulfate
Empirical Formula (Hill Notation):
C38H52N6O7 · H2SO4
CAS Number:
229975-97-7
Molecular Weight:
802.93
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥95% (HPLC)

form

powder

optical activity

[α]/D -40 to -50°, c = 1 in methanol: water (1:1)

storage condition

desiccated

color

white to beige

solubility

H2O: 2 mg/mL, clear

shipped in

wet ice

storage temp.

2-8°C

SMILES string

O[C@@H](CN(CC1=CC=C(C2=CC=CC=N2)C=C1)NC([C@@H](NC(OC)=O)C(C)(C)C)=O)[C@@H](NC([C@@H](NC(OC)=O)C(C)(C)C)=O)CC3=CC=CC=C3.O=S(O)OO

InChI

1S/C38H52N6O7.H2O4S/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28;1-5(2,3)4/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47);(H2,1,2,3,4)/t29-,30-,31+,32+;/m0./s1

InChI key

DQSGVVGOPRWTKI-QVFAWCHISA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Atazanavir sulfate is the prodrug of Atazanavir, an antiviral HIV protease inhibitor.

Pictograms

Health hazardCorrosion
GHS08,GHS05

Signal Word

Danger

Hazard Statements

H318,H372

Hazard Classifications

Eye Dam. 1 - STOT RE 1

Target Organs

Heart,Liver

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jose R Castillo-Mancilla et al.
The Journal of antimicrobial chemotherapy, 71(6), 1609-1618 (2016-02-20)
The multinational PEARLS (ACTG A5175) study, conducted mainly in resource-limited settings, identified an increased treatment failure rate among HIV-infected individuals randomized to once-daily unboosted atazanavir, didanosine-EC, and emtricitabine compared with efavirenz-based regimens. We evaluated associations between selected human genetic polymorphisms
Lisa Rosenblatt et al.
BMC infectious diseases, 16, 492-492 (2016-09-20)
A previous cohort study indicated that atazanavir (ATV), a protease inhibitor used for HIV treatment, is not associated with an increased risk of cardiovascular (CV) events. The objective of this study was to compare the risk of CV events among
Vincent Calvez et al.
The Journal of antimicrobial chemotherapy, 72(1), 19-28 (2016-09-23)
For many patients living with HIV-1, the efficacy of combined ART (cART) has made the infection turn to a chronic disease. Because cART is associated with a risk of long-term toxicity, switching patients with virological success to another therapy remains

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service